Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 3/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11159331 | 0.82 | KDM4E (0.48) | ADRB2ADRB1CYP2D6ADRB3KDM4E | |
| SCHEMBL11236751 | 0.82 | KDM4E (0.44) | ADRB2ADRB1CYP2D6ADRB3KDM4E | |
| SCHEMBL23976280 | 0.81 | ADRB2 (0.53) | ADRB2ADRB1CYP2D6ADRB3PTGS1 | |
| SCHEMBL11227378 | 0.80 | KDM4E (0.42) | ADRB2ADRB1CYP2D6ADRB3KDM4E | |
| SCHEMBL12441481 | 0.79 | KDM4E (0.46) | ADRB2ADRB1ADRB3KDM4EHTT | |
| SCHEMBL11340743 | 0.79 | USP2 (0.58) | ADRB2ADRB1MEN1HTTKMT2A | |
| SCHEMBL9759886 | 0.78 | ADRB2 (0.50) | ADRB2ADRB1CYP2D6ADRB3PTGS1 | |
| SCHEMBL12441491 | 0.77 | USP2 (0.61) | ADRB2ADRB1MEN1HTTKMT2A | |
| SCHEMBL20670875 | 0.77 | USP2 (0.61) | ADRB2ADRB1MEN1HTTKMT2A | |
| SCHEMBL23334641 | 0.77 | USP2 (0.61) | ADRB2ADRB1MEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017031392-A1 | LIPID COMPOUNDS FOR TREATMENT OF OBESITY, HYPERTENSION AND METABOLIC SYNDROME | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2017-02-23 | — | — | WO | disclosed |
| US-8871983-B2 | Lipid compounds for suppression of tumorigenesis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871983-B2 | Lipid compounds for suppression of tumorigenesis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20120059003-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-03-08 | — | — | US | disclosed |
| US-20110177108-A1 | LIPID COMPOUNDS FOR SUPRESSION OF TUMORIGENESIS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2010017550-A2 | LIPID COMPOUNDS FOR SUPRESSION OF TUMORIGENESIS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177108-A1 | LIPID COMPOUNDS FOR SUPRESSION OF TUMORIGENESIS | SREBF2, SREBF1, PLIN1 | ADRB2 4718/4885ADRB1 4656/4885CYP2D6 4009/4885 |
| US-20120059003-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | ADRB2 4636/4885ADRB1 4388/4885CYP2D6 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.